상세 보기

Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

Lee, Ki Hyeong;
Ahn, Myung-Ju;
Han, Ji-Youn;
Kim, Sang-We;
Cho, Eun Kyung;
... Lee, Jong-Seok;
... Shin, Sang Won;
외 13명

제목: Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

저자: Lee, Ki Hyeong; Ahn, Myung-Ju; Han, Ji-Youn; Kim, Sang-We; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won; Shim, Byoung Yong; Kim, Jin-Soo; Chun, Sang Hoon; Lee, Sung Sook; Min, Young Joo; Shin, Sang Won; Hong, Min Hee; Sun, Jong-Mu; Byun, Hae Mi; Cho, Byoung Chul

DOI: 10.1200/jco.2020.38.15_suppl.9572

발행일: 2020-05-20

학회명: 2020 ASCO Annual Meeting

개최국가: 미국

학회 개최일: 2020-05 ~ 2020-05

언어: ENG